Significance of preoperative hematologic scoring in predicting death among patients with non-metastatic renal cell carcinoma undergoing nephrectomy

Copyright © 2021. Published by Elsevier Taiwan LLC..

PURPOSE: Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are hematologic scoring and indicators of the systemic inflammatory response. The increasing use of NLR and PLR have been associated with poor outcome in various types of malignancy. We evaluated the effect of NLR and PLR on survival outcomes of nonmetastatic renal cell carcinoma (RCC).

MATERIALS AND METHODS: We retrospectively review 150 patients who had undergone nephrectomy for nonmetastatic RCC between 2006 and 2016. Cancer specific survival (CSS) was assessed using Kaplan-Meier method and compared using log-rank test. We applied univariate and multivariate Cox regression model to analyze the association of NLP and PLR with clinical outcome.

RESULTS: At median follow up of 33 months, 45 patients had died. High PLR (>100) was an independent prognostic hematologic marker for CSS (hazard ratio [HR] 2.61, 95% confidence interval [CI],1.08-6.31; P = 0.034). Univariate analysis identified elevated NLR (p = 0.005), and anemia (p = 0.023) were significantly associated with CSS.

CONCLUSION: Elevated PLR is a strong hematologic prognosis factor in term of survival for patients with nonmetastatic RCC undergoing nephrectomy with curative intent. The PLR is an easily obtained biomarker which is useful for preoperative risk stratification.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:44

Enthalten in:

Asian journal of surgery - 44(2021), 7 vom: 19. Juli, Seite 952-956

Sprache:

Englisch

Beteiligte Personen:

Attawettayanon, Worapat [VerfasserIn]
Choorit, Teeranop [VerfasserIn]
Chalieopanyarwong, Virote [VerfasserIn]
Pripatnanont, Choosak [VerfasserIn]

Links:

Volltext

Themen:

Journal Article
Neutrophil to lymphocyte ratio
Platelet to lymphocyte ratio
Prognosis
Renal cell carcinoma

Anmerkungen:

Date Completed 31.08.2021

Date Revised 31.08.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.asjsur.2021.01.029

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM321809343